MRZM (Marizyme) ROC %: -12.42% (As of Sep. 2024)

What is Marizyme ROC %?

Marizyme MRZM -99.67% 12 ROC % is -12.42% as of Sep. 2024. GuruFocus rates MRZM with a GF Score™ of 12/100.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Marizyme's annualized return on capital (ROC %) for the quarter that ended in Sep. 2024 was -12.42%.

As of today (2026-06-26), Marizyme's WACC % is 0.00%. Marizyme's ROC % is 0.00% (calculated using TTM income statement data). Marizyme earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Marizyme (OTCPK:MRZM) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Marizyme's WACC % is 0.00%. Marizyme's ROC % is 0.00% (calculated using TTM income statement data). Marizyme earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Marizyme ROC % Related Terms

Marizyme ROC % Historical Data

* Premium members only.

The historical data trend for Marizyme's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marizyme ROC % Chart

Marizyme Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROC %

Get a 7-Day Free Trial

-3.70

-15.90

-16.57

-25.81

-49.81

Marizyme Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROC %	Get a 7-Day Free Trial															-28.46	-52.26	-12.90	-15.06	-12.42

12GF Score

Marizyme Inc MRZM

ROC % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Marizyme ROC % Calculation

Marizyme's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

	ROC % (A: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2022 )	+	Invested Capital (A: Dec. 2023 ))	/ count )
=	-19.842 * ( 1 - 0% )	/	( (38.43	+	41.242)	/ 2 )
=	-19.842	/	39.836
=	-49.81 %

where

	Invested Capital		(A: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	38.688	-	1.225	-	( 0.511	-	max(0, 2.922	-	1.955	+	0.511	))
=	38.43

	Invested Capital		(A: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	22.015	-	2.447	-	( 0.148	-	max(0, 22.643	-	0.969	+	0.148	))
=	41.242

Marizyme's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	-5.42 * ( 1 - 0% )	/	( (40.608	+	46.704)	/ 2 )
=	-5.42	/	43.656
=	-12.42 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	21.535	-	3.557	-	( 0.005	-	max(0, 23.552	-	0.922	+	0.005	))
=	40.608

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	21.256	-	3.674	-	( 0.064	-	max(0, 29.977	-	0.855	+	0.064	))
=	46.704

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -12.42% mean?

Marizyme (MRZM) has a ROC % of -12.42% as of Sep. 2024. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Marizyme and its competitors.

Is Marizyme's ROC % too high?

Marizyme's current ROC % is -12.42%. Overall, Marizyme has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does Marizyme's ROC % compare to CNBX and XSNX?

Marizyme's ROC % of -12.42% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Biotechnology company?

A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Marizyme and its competitors. Marizyme's current ROC % is -12.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Marizyme stock overvalued right now?

Marizyme (MRZM) has a current ROC % of -12.42%. The current ROC % is -12.42%. Marizyme's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For Marizyme (MRZM), the current ROC % is -12.42% as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marizyme Business Description

Industry Healthcare Biotechnology

Comparable Companies CNBX XSNX NBIO BTAX PXMD ARTHQ GRTSQ MTEM ENDV GBLX VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX

Address 555 Heritage Drive, Suite 205, Jupiter, FL, USA, 33458

Website https://www.marizyme.com

Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.

12GF Score

Get the complete analysis for MRZM

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View MRZM Analysis

See ROC % data for all stocks →